CD8A and COVID-19: Finally, Jung et al. demonstrated that SARS-CoV-2-specific CD4+ and CD8+ T cell responses in COVID-19 convalescent patients are maintained up to 317 days post-symptom onset (DPSO), regardless of the severity of COVID-19 [15].